KENT AND MEDWAY HEALTH ECONOMY NATIONAL TARIFF EXCLUDED DRUGS Summary of Current Arrangements 2017/18 Contents NATIONAL TARIFF EXCLUDED DRUGS: SUMMARY OF CURRENT ARRANGEMENTS .................................. 10 MANAGEMENT OF NATIONAL TARIFF EXCLUDED DRUGS ...................................................................... 11 Payment Arrangements ................................................................................................................................... 12 Responsibilities ................................................................................................................................................ 12 Amendment Sheet ........................................................................................................................................... 13 3, 4 DIAMINOPYRIDINE .................................................................................................................................... 14 ABACAVIR ......................................................................................................................................................... 15 ABACAVIR with DOLUTEGRAVIR and LAMIVUDINE ......................................................................................... 16 ABACAVIR with LAMIVUDINE ........................................................................................................................... 17 ABALOPARATIDE .............................................................................................................................................. 18 ABATACEPT ...................................................................................................................................................... 19 ABATACEPT (CCG) ............................................................................................................................................ 20 ABIRATERONE .................................................................................................................................................. 21 ADALIMUMAB .................................................................................................................................................. 22 ADALIMUMAB (CCG) ........................................................................................................................................ 23 ADEFOVIR ......................................................................................................................................................... 24 AFAMELANOTIDE ............................................................................................................................................. 25 AFATINIB .......................................................................................................................................................... 26 AFLIBERCEPT .................................................................................................................................................... 27 AFLIBERCEPT (CCG) .......................................................................................................................................... 28 AGALSIDASE ALFA ............................................................................................................................................ 29 AGALSIDASE BETA ............................................................................................................................................ 30 AGANIRSEN ...................................................................................................................................................... 31 ALBUTREPENONACOG ALFA ............................................................................................................................ 32 ALDESLEUKIN ................................................................................................................................................... 33 ALEMTUZUMAB ............................................................................................................................................... 34 ALGLUCOSIDASE ALFA ...................................................................................................................................... 35 ALIPOGENE TIPARVOVEC ................................................................................................................................. 36 ALIROCUMAB ................................................................................................................................................... 37 ALITRETINOIN ................................................................................................................................................... 38 ALPHA-1 ANTITRYPSIN ..................................................................................................................................... 39 ALPHA MANNOSIDASE RECOMBINANT HUMAN ............................................................................................. 40 AMBRISENTAN ................................................................................................................................................. 41 AMIFAMPRIDINE PHOSPHATE ......................................................................................................................... 42 AMIKACIN INHALATION ................................................................................................................................... 43 AMIKACIN LIPOSOMAL .................................................................................................................................... 44 AMPHOTERICIN LIPOSOMAL ............................................................................................................................ 45 ANAKINRA ........................................................................................................................................................ 46 ANAKINRA (CCG) .............................................................................................................................................. 47 ANIDULAFUNGIN.............................................................................................................................................. 48 ANTIHAEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX .............................................................. 49 ANTILYMPHOCYTE GLOBULIN .......................................................................................................................... 50 ANTITHROMBIN III ........................................................................................................................................... 51 ANTITHYMOCYTE IMMUNOGLOBULIN ............................................................................................................ 52 APREMILAST ..................................................................................................................................................... 53 APREMILAST (CCG) ........................................................................................................................................... 54 ARAGAM® ........................................................................................................................................................ 55 1 ASFOTASE ALPHA ............................................................................................................................................. 56 ASUNAPREVIR with DACLATASVIR ................................................................................................................... 57 ATACICEPT ........................................................................................................................................................ 58 ATALUREN ........................................................................................................................................................ 59 ATAZANAVIR .................................................................................................................................................... 60 ATAZANAVIR and COBICISTAT ......................................................................................................................... 61 AVATROMBOPAG ............................................................................................................................................. 62 AXITINIB ........................................................................................................................................................... 63 AZACITIDINE ..................................................................................................................................................... 64 AZATHIOPRINE ................................................................................................................................................. 65 AZTREONAM LYSINE ........................................................................................................................................ 66 BARICITINIB ...................................................................................................................................................... 67 BARICITINIB (CCG) ............................................................................................................................................ 68 BASILIXIMAB ...................................................................................................................................................